AstraZeneca announces breakthrough in breast cancer treatment drug.

On June 1st, AstraZeneca updated information on the effectiveness of its breast cancer drug Camizestrant, with results considered groundbreaking, showing a more than 50% reduction in the risk of tumor growth.

VietnamPlus•02/06/2025

According to the Vietnam News Agency correspondent in the UK, AstraZeneca updated information on June 1st regarding the effectiveness of its breast cancer drug Camizestrant, with results considered groundbreaking.

Information released by the British-Swedish pharmaceutical company at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, shows that this drug, currently in late-stage trials, has demonstrated effectiveness in reducing the risk of tumor growth or death by more than 50% in breast cancer patients.

A global study conducted by AstraZeneca in collaboration with the London Cancer Research Institute, the NHS Royal Marsden Trust, and the Curie Institute in Paris (France) showed that patients with advanced-stage breast cancer who were hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) and treated with Camizestrant in combination with a CDK4/6 inhibitor had a 56% reduced risk of cancer progression.

During the testing of the new drug, an improved blood test method, called liquid biopsy or circulating tumor DNA (ctDNA), was used to detect tumor DNA and identify patients at high risk for tumor mutations before tumors could be detected on scanners. This test allowed patients to be treated with the new drug at an earlier stage.

You may also like

Sweet potatoes – a food that nourishes the spleen and stomach: 5 benefits of eating them for breakfast.Health and Life - Sweet potatoes are a food rich in fiber, vitamins, and minerals, often chosen for breakfast. However, is eating sweet potatoes every day really good for you, and who should limit their consumption of this food?

4 diseases that can be detected early through regular health checkups.Many dangerous diseases can silently progress for years without causing any obvious symptoms. Patients continue to eat, work, and live normally, leading them to not realize they are ill.

Is kidney disease hereditary? Experts point out who is at high risk.Kidney disease commonly occurs in people with diabetes or high blood pressure. However, genetic factors also influence the risk of developing the disease.

According to AstraZeneca, the experimental drug Camizestrant prevented estrogen from binding to cancer cells and destroyed the cells' receptors, making them less resistant to treatment.

The results showed that in patients using the new drug in combination with existing treatment, disease progression slowed by an average of 16 months, compared to 9.2 months in the group using only existing treatment. The trial also found that treatment with the new drug resulted in a significantly longer-lasting quality of life for patients compared to current standards.

In the UK, around 55,000 women are diagnosed with breast cancer each year, and 11,500 die from it, with approximately 70% of patients having HR+ or HER2- breast cancer.
Experts expect this finding could open up new treatment strategies for patients with this common type of cancer. The findings from the trial were published simultaneously in the New England Journal of Medicine.

AstraZeneca currently has nine cancer drugs approved for 37 different types and stages of cancer. With the success of the Camizestrant trial, the British-Swedish pharmaceutical group estimates the new treatment could generate an additional $5 billion in revenue during its peak year.

United States - Vietnam: Don't miss

Ambassador Nguyen Quoc Dung visits and works in Minnesota, USA.From June 28-30, the Vietnamese Ambassador to the United States, Nguyen Quoc Dung, paid a visit and worked in Minnesota.

Vietnam encourages US businesses to expand investment in high technology.On the morning of June 26th, at the Government Headquarters, Deputy Prime Minister Ho Quoc Dung received Mr. Jeff Place, Supply Chain Director of Coherent Group (USA). During the meeting, the Deputy Prime Minister affirmed that Vietnam encourages US businesses to expand investment, especially in high-tech, innovation, and semiconductor industries.

Encourage U.S. businesses to expand investment in high-tech sectors.Deputy Prime Minister Ho Quoc Dung said that Vietnam welcomes US businesses to continue expanding their operations in Vietnam, especially in high-tech industries and sectors with high added value.

(VNA/Vietnam+)

Source: https://www.vietnamplus.vn/astrazeneca-cong-bo-dot-pha-cua-thuoc-dieu-tri-ung-thu-vu-post1041936.vnp